Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16239134 | 0.89 | THRB (0.38) | KMT2ASMN1; SMN2MAPTGAAUSP2 | |
| SCHEMBL16235591 | 0.88 | KDM4E (0.45) | LMNAKMT2AMAPTGAAUSP2 | |
| SCHEMBL16239303 | 0.85 | TYMS (0.41) | KMT2AMAPTMEN1USP2HSD17B10 | |
| SCHEMBL16235966 | 0.82 | NPC1 (0.43) | LMNAPPARGKMT2ASMN1; SMN2MAPT | |
| SCHEMBL16239219 | 0.82 | HSD17B10 (0.48) | LMNAMETAP2METAP1HDAC6PPARG | |
| SCHEMBL16235949 | 0.82 | LMNA (0.49) | LMNAMETAP2METAP1HDAC6PPARG | |
| SCHEMBL16239185 | 0.81 | ALDH1A1 (0.47) | KMT2ASMN1; SMN2MAPTMEN1HSD17B10 | |
| SCHEMBL15233903 | 0.81 | LMNA (0.48) | LMNAMETAP2METAP1HDAC6PPARG | |
| SCHEMBL16235702 | 0.81 | LMNA (0.43) | LMNAKMT2ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL16236443 | 0.81 | NPC1 (0.40) | LMNAPPARGKMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005860-B2 | Catalyst components for the polymerization of olefins | BASELL POLIOLEFINE ITALIA S.R.L. (IT) | 2018-06-26 | — | — | US | disclosed |
| EP-2997049-B1 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE ITALIA SRL (IT) | 2017-08-23 | — | — | EP | disclosed |
| US-20170166667-A1 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE ITALIA S.R.L. (IT) | 2017-06-15 | — | — | US | disclosed |
| US-9644051-B2 | Catalyst components for the polymerization of olefins | BASELL POLIOLEFINE ITALIA S.R.L. (IT) | 2017-05-09 | — | — | US | disclosed |
| US-20160090428-A1 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS | Basell Poliolefine Italia, s.r.l. (IT) | 2016-03-31 | — | — | US | disclosed |
| EP-2803679-A1 | Catalyst components for the polymerization of olefins | Basell Poliolefine Italia S.r.l. (IT) | 2014-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005860-B2 | Catalyst components for the polymerization of olefins | OXER1, OXSR1, NR0B2 | LMNA 4419/4885METAP2 3581/4885METAP1 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.